Do Kenny, Kawana Eric, Tian Sisi, Bigcas Jo-Lawrence
Department of Otolaryngology-Head and Neck Surgery, Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas, Las Vegas, NV, USA.
Ear Nose Throat J. 2024 Apr 22:1455613241248119. doi: 10.1177/01455613241248119.
Warthin's tumors of the parotid gland can be safely observed. Definitive treatment usually requires parotidectomy under general anesthesia. The decision to operate on Warthin's tumors of the parotid gland can be complicated in patients who wish to avoid risks of surgery and general anesthesia. This systematic review explores the potential of radiofrequency ablation (RFA) as a minimally invasive alternative. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) model was used to collect 3 relevant studies that focused on RFA treatment for Warthin's tumors. The cumulative averages for tumor size and cosmetic scores were then quantified for patients with Warthin's tumors who underwent RFA therapy. The PRISMA systematic review method was employed to the PubMed and EMBASE databases. The comprehensive search term "Warthin Tumor Treatment" yielded 1299 articles from the years 1955 to 2023, 3 of which met inclusion criteria and were then selected. The 3 quantitative studies collectively assessed 37 patients with Warthin's tumors treated with RFA. Patients experienced an average tumor size reduction of 85.03% at 12 months post-RFA. There were minimal complications associated with RFA in these patients. This study suggests that RFA is an alternative to parotidectomy for the symptomatic treatment of Warthin's tumors. RFA procedures demonstrated substantial tumor size reduction with few complications. However, further meta-analysis and comparison with alternative treatments is warranted to establish RFA's role in treatment of Warthin's tumors. The study is limited by its reliance on only 2 databases and a lack of comprehensive examination of different RFA settings.
腮腺沃辛瘤可以安全地进行观察。确定性治疗通常需要在全身麻醉下进行腮腺切除术。对于希望避免手术和全身麻醉风险的腮腺沃辛瘤患者，决定是否进行手术可能会很复杂。本系统评价探讨了射频消融（RFA）作为一种微创替代方法的潜力。采用系统评价和荟萃分析的首选报告项目（PRISMA）模型收集了3项关注RFA治疗沃辛瘤的相关研究。然后对接受RFA治疗的沃辛瘤患者的肿瘤大小和美容评分的累积平均值进行量化。将PRISMA系统评价方法应用于PubMed和EMBASE数据库。综合检索词“沃辛瘤治疗”在1955年至2023年期间产生了1299篇文章，其中3篇符合纳入标准并被选中。这3项定量研究共评估了37例接受RFA治疗的沃辛瘤患者。患者在RFA术后12个月时平均肿瘤大小缩小了85.03%。这些患者中与RFA相关的并发症极少。本研究表明，RFA可作为腮腺沃辛瘤症状性治疗中腮腺切除术的替代方法。RFA手术显示肿瘤大小显著缩小，并发症很少。然而，需要进一步进行荟萃分析并与其他治疗方法进行比较，以确定RFA在沃辛瘤治疗中的作用。该研究的局限性在于仅依赖2个数据库，且缺乏对不同RFA设置的全面检查。
